Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Analysts at TD Cowen

Posted by Geri Gentry on Sep 9th, 2026

Equities research analysts at TD Cowen started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) in a note issued to investors on Wednesday, Briefing.com reports. The firm set a “buy” rating on the stock.

A number of other equities research analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. Raymond James Financial began coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They issued an “outperform” rating and a $56.00 target price for the company. Oppenheimer initiated coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Get Our Latest Research Report on FTH

Sensei Biotherapeutics Trading Up 0.5%

NASDAQ FTH traded up $0.20 on Wednesday, hitting $39.41. 7,240 shares of the stock were exchanged, compared to its average volume of 214,615. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14. The firm has a 50-day simple moving average of $30.48. The firm has a market cap of $1.02 billion, a P/E ratio of -0.28 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Analysts forecast that Sensei Biotherapeutics will post -13.18 EPS for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In other news, CEO Anand Kiran Parikh acquired 2,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Brian C. Stephenson acquired 5,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the purchase, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This trade represents a 11.99% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 49,494 shares of company stock valued at $1,188,822 in the last 90 days. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares during the period. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics in the second quarter valued at about $307,000. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the 1st quarter valued at approximately $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.